303 related articles for article (PubMed ID: 25271055)
1. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
Wein MN; Spatz J; Nishimori S; Doench J; Root D; Babij P; Nagano K; Baron R; Brooks D; Bouxsein M; Pajevic PD; Kronenberg HM
J Bone Miner Res; 2015 Mar; 30(3):400-11. PubMed ID: 25271055
[TBL] [Abstract][Full Text] [Related]
2. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
[TBL] [Abstract][Full Text] [Related]
3. Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.
Baertschi S; Baur N; Lueders-Lefevre V; Voshol J; Keller H
J Biol Chem; 2014 Sep; 289(36):24995-5009. PubMed ID: 25012661
[TBL] [Abstract][Full Text] [Related]
4. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
5. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
7. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
8. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
Zhao G; Huang BL; Rigueur D; Wang W; Bhoot C; Charles KR; Baek J; Mohan S; Jiang J; Lyons KM
J Bone Miner Res; 2018 Jun; 33(6):1076-1089. PubMed ID: 29351359
[TBL] [Abstract][Full Text] [Related]
9. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
[TBL] [Abstract][Full Text] [Related]
10. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
11. Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.
Ryan ZC; Craig TA; Salisbury JL; Carpio LR; McGee-Lawrence M; Westendorf JJ; Kumar R
Biochem Biophys Res Commun; 2014 May; 448(1):83-8. PubMed ID: 24780398
[TBL] [Abstract][Full Text] [Related]
12. A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction.
Sato T; Verma S; Andrade CDC; Omeara M; Campbell N; Wang JS; Cetinbas M; Lang A; Ausk BJ; Brooks DJ; Sadreyev RI; Kronenberg HM; Lagares D; Uda Y; Pajevic PD; Bouxsein ML; Gross TS; Wein MN
Nat Commun; 2020 Jul; 11(1):3282. PubMed ID: 32612176
[TBL] [Abstract][Full Text] [Related]
13. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss.
Baroi S; Czernik PJ; Chougule A; Griffin PR; Lecka-Czernik B
Bone; 2021 Jun; 147():115913. PubMed ID: 33722775
[TBL] [Abstract][Full Text] [Related]
14. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
15. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
[TBL] [Abstract][Full Text] [Related]
16. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
17. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
Bonnet N; Conway SJ; Ferrari SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15048-53. PubMed ID: 22927401
[TBL] [Abstract][Full Text] [Related]
18. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D
St John HC; Hansen SJ; Pike JW
J Steroid Biochem Mol Biol; 2016 Nov; 164():277-280. PubMed ID: 26361013
[TBL] [Abstract][Full Text] [Related]
19. Mef2c regulates bone mass through Sost-dependent and -independent mechanisms.
Morfin C; Sebastian A; Wilson SP; Amiri B; Murugesh DK; Hum NR; Christiansen BA; Loots GG
Bone; 2024 Feb; 179():116976. PubMed ID: 38042445
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.
Ryan ZC; Ketha H; McNulty MS; McGee-Lawrence M; Craig TA; Grande JP; Westendorf JJ; Singh RJ; Kumar R
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6199-204. PubMed ID: 23530237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
